

# Pharmacotherapy for OAB includes antimuscarinics and beta-3 agonists.<sup>1</sup>

Antimuscarinics are associated with challenges such as:

## Poor persistence to therapy



Most patients stop antimuscarinic agents within the first year because of lack of efficacy, adverse events, and/or cost<sup>2,3</sup>

## Antimuscarinic cycling



Patients can sometimes cycle from 1 to 6 antimuscarinics without adequate relief from OAB symptoms<sup>4</sup>

## Anticholinergic burden in elderly



Elderly patients are at a higher risk of cognitive dysfunction, alteration in central nervous system metabolism, and brain atrophy with prolonged use<sup>3</sup>

# Beta-3 agonists such as BETMIGA™ can help avoid the side-effects of antimuscarinics while providing optimal symptom relief



OAB, overactive bladder; QoL, quality of life.

References: 1. EAU. Guidelines on urinary incontinence. Presented at the European Association of Urology (EAU) Annual Congress; 15-19 Mar 2019b, Barcelona, Spain. Available at: <https://uroweb.org/guidelines/urinary-incontinence/>. Accessed 14 Sept 2021. 2. Kim TH, et al. *Investig Clin Urol*. 2016;57:84-93. 3. Hamblar AK, et al. *Eur Urol*. 2018;73:596-605. 4. Chancellor MB, et al. *Int Urol Nephrol*. 2016;48:1029-1036. 5. Nish VM, et al. *J Urol*. 2013;189:1388-1395. 6. Kelleher C, et al. *Eur Urol*. 2018;74:324-333. 7. Chapple C, et al. *Eur Urol*. 2015;67:11-14. 8. Drake MJ, et al. *Eur Urol*. 2016;70:136-145. 9. Lozano-Ortega G, et al. *Drugs Aging*. 2020;37:801-816. 10. Nasir J, et al. *Pharmacoecon Open*. 2017;1:25-36. 11. Kato D, et al. *Low Urin Tract Symptoms*. 2019;11:152-161. 12. Chapple CR, et al. *World J Urol*. 2014;32:1565-1572. 13. Chapple CR, et al. *Int Urogynecol J*. 2013;24:1447-1458. 14. Freeman R, et al. *Curr Med Res Opin*. 2018;34:785-793.